文献速递前列腺癌

进展导向治疗对转移性去势抵抗性前列腺癌生存的影响:MEDCARE 3期试验

The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.
PubMed 文献 · BJU Int · 2024-11-06

MEDCARE 3期试验为多中心、随机、前瞻性研究,计划按1:1随机分配246例寡进展性转移性去势抵抗性前列腺癌(mCRPC)患者,比较标准治疗(监测或下一线系统治疗)与进展导向治疗(PDT)在继续当前系统治疗基础上的疗效。主要终点为总生存期(OS),次要终点包括生活质量、影像学无进展生存期(PFS)、改良PFS、前列腺癌特异性生存期及PDT相关毒性。该试验是首个以OS为主要终点、在寡进展性mCRPC中评估PDT的随机3期试验。

要点

  • MEDCARE 3期试验计划随机分配246例寡进展性mCRPC患者,按1:1比较标准治疗与PDT。
  • 主要终点为OS,次要终点包括生活质量、影像学PFS、改良PFS、前列腺癌特异性生存期及PDT毒性。
  • 分层因素包括进展病灶数目(1个 vs ≥1个)、进展病灶位置(局部复发、N或M1a vs M1b或M1c)及既往系统治疗。

核心结论

  • 该试验旨在评估PDT对寡进展性mCRPC患者OS的影响。
  • 这是首个在寡进展性mCRPC中评估PDT、以OS为主要终点的随机3期试验。

研究设计与样本

  • 多中心、随机、前瞻性3期试验,计划按1:1随机分配246例寡进展性mCRPC患者。
  • 患者随机接受标准治疗(监测或NEST)或PDT,同时继续当前系统治疗。
  • 按进展病灶数目(1个 vs ≥1个)、进展病灶位置(局部复发、N或M1a vs M1b或M1c)及既往系统治疗(pADT vs pADT+雄激素受体靶向药物或既往接受过多西他赛)进行分层。

关键数值与推荐

  • 主要终点为OS;次要终点包括生活质量、影像学PFS、改良PFS、前列腺癌特异性生存期及PDT相关毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic castration-refractory prostate cancer (mCRPC) presents a therapeutic challenge despite advancements in treatment. Once mCRPC is attained, patients face limited survival prospects. Next-line systemic treatment (NEST) is the standard of care for progressive mCRPC, encompassing various therapeutic options with associated toxicity and costs. In patients with oligoprogressive mCRPC, data suggest that progression-directed therapy (PDT), such as metastasectomy or stereotactic body radiotherapy, delays the initiation of NEST. METHODS AND DESIGN: The MEDCARE phase III trial aims to assess the impact of PDT on overall survival (OS) in oligoprogressive mCRPC. In this multicentric, randomised, prospective trial, we aim to randomise 246 patients in 1:1 allocation ratio between the standard-of-care therapy (surveillance or NEST) or PDT while continuing the current systemic treatment. Patients will be stratified based on number of progressive lesions (one vs ≥one), location of progressive lesions (local recurrence, N or M1a vs M1b or M1c) and previous systemic therapy (palliative androgen-deprivation therapy [pADT] vs pADT + androgen receptor-targeted agent or patients who received docetaxel in the past). The primary endpoint is OS, and the secondary endpoints include quality of life, radiographic progression-free survival (PFS), modified PFS, prostate cancer-specific survival and PDT-induced toxicity. DISCUSSION: This is the first randomised phase 3 trial in the setting of PDT in patients with oligoprogressive mCRPC with OS as the primary endpoint.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Rans K, Goffin K, Joniau S, et al. The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial. BJU Int. 2024. PMID: 39506181. doi:10.1111/bju.16574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。